logicbio
therapeutics
announces
closing
public
offering
common
stock
full
exercise
underwriters
option
purchase
additional
shares
lexington
globe
newswire
logicbio
therapeutics
nasdaq
logc
logicbio
company
dedicated
extending
reach
genetic
medicine
pioneering
targeted
delivery
platforms
today
announced
closing
previously
announced
underwritten
public
offering
shares
common
stock
price
public
per
share
includes
exercise
full
underwriters
option
purchase
additional
shares
common
stock
gross
proceeds
logicbio
offering
million
deducting
underwriting
discounts
commissions
offering
expenses
payable
logicbio
jefferies
barclays
william
blair
acted
joint
managers
chardan
acted
lead
manager
offering
logicbio
intends
use
net
proceeds
offering
support
clinical
development
progress
development
generide
next
generation
capsid
platforms
expand
pipeline
product
candidates
indications
may
targeted
platforms
balance
fund
working
capital
capital
expenditures
general
corporate
purposes
shares
common
stock
described
offered
logicbio
pursuant
effective
shelf
registration
statement
form
file
declared
effective
securities
exchange
commission
sec
november
preliminary
prospectus
supplement
related
offering
filed
sec
september
final
prospectus
supplement
related
offering
filed
sec
october
copies
final
prospectus
supplement
accompanying
prospectus
may
obtained
jefferies
llc
attention
equity
syndicate
prospectus
department
madison
avenue
floor
ny
telephone
email
barclays
capital
c
broadridge
financial
solutions
long
island
avenue
edgewood
ny
telephone
email
barclaysprospectus
william
blair
company
attention
prospectus
department
north
riverside
plaza
chicago
il
email
prospectus
telephone
electronic
copies
final
prospectus
supplement
accompanying
prospectus
also
available
website
sec
press
release
constitute
offer
sell
solicitation
offer
buy
securities
offering
shall
sale
securities
jurisdiction
offer
solicitation
sale
would
unlawful
prior
registration
qualification
securities
laws
jurisdiction
logicbio
therapeutics
logicbio
therapeutics
dedicated
extending
reach
genetic
medicine
pioneering
targeted
delivery
platforms
logicbio
proprietary
genome
editing
technology
platform
generide
enables
integration
therapeutic
transgene
without
nucleases
exogenous
promoters
harnessing
native
process
homologous
recombination
logicbio
also
developing
next
generation
capsid
platform
use
gene
editing
gene
therapies
logicbio
developing
highly
potent
vectors
internal
development
candidates
potentially
business
development
collaborations
logicbio
headquartered
lexington
mass
statements
certain
statements
contained
press
release
including
relating
expected
use
proceeds
offering
statements
involve
number
risks
uncertainties
could
cause
actual
results
differ
materially
statements
risks
uncertainties
include
limited
risks
uncertainties
associated
general
economic
conditions
including
result
ongoing
pandemic
risks
identified
time
time
reports
file
sec
including
annual
report
form
quarterly
reports
form
preliminary
prospectus
supplement
accompanying
prospectus
related
offering
file
sec
available
statements
press
release
speak
date
document
undertake
obligation
update
revise
statements
business
subject
substantial
risks
uncertainties
including
referenced
investors
potential
investors
others
give
careful
consideration
risks
uncertainties
contact
matthias
jaffe
chief
financial
officer
mjaffe
